Effect of 1% sodium alendronate in the non-surgical treatment of periodontal intraosseous defects: a 6-month clinical trial

• Autor(a) principal: Bernardo Carvalho Dutra
• Data de Publicação: 2017
• Outros Autores: Alcione Maria Soares Dutra de Oliveira, Peterson Antonio Dutra de Oliveira, Flávio Ricardo Manzi, Sheila Cavalca Cortelli, Luis Otávio de Miranda Cota, Fernando de Oliveira Costa
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.1590/1678-7757-2016-0252; http://hdl.handle.net/1843/68805
• topic: alendronate sodium; intraosseus defects; non-surgical periodontal therapy; Periodontitis Sodium; alendronate; Biphosphonates; Periodontitis; Dental scaling; Alendronate; Sodium; Periodontitis; Dental scaling; Bone and bones; Cone-beam computed tomography

Background and objectives: Few studies have evaluated the effect of the topical application of sodium alendronate (ALN) on the treatment of intrabuccal bone defects, especially those caused by periodontitis. This 6-month randomized placebo controlled clinical trial aimed at evaluating the effect of non-surgical periodontal treatment associated with the use of 1% ALN, through clinical evaluations and cone-beam computed tomography (CBCT). Material and methods: Twenty individuals with chronic periodontitis underwent periodontal examination at the baseline as well as 3 and 6 months after periodontal treatment, registering clinical attachment level (CAL), periodontal probing depth (PPD), and bleeding on probing (BOP) as the clinical outcomes. After manual scaling and root planing, 40 bilateral sites with interproximal vertical bone defects were randomly treated with either 1% ALN gel or a placebo. Bone defects were evaluated through CBCT at the baseline and 6 months post-treatment. The clinical and CBCT parameters were compared using the Wilcoxon and Friedman tests (p<0.05). Results: Although ALN produced a greater CAL gain when compared to the placebo at 6 months post-treatment (p=0.021), both treatments produced similar effects on the PPD, BOP, and bone height. Significant differences in bone fill were observed only in patients of the ALN group (4.5 to 3.8 mm; p=0.003) at 6 months post-treatment.